{"version": "https://jsonfeed.org/version/1.1", "title": "Sharemaestro Newsreel: United States Healthcare news", "home_page_url": "https://sharemaestro.com/newsreel/us/healthcare/", "feed_url": "https://sharemaestro.com/newsreel/us/healthcare/feed.json", "description": "Latest Healthcare company headlines from United States, newest first, with industry sections, source links and company research.", "language": "en", "items": [{"id": "watch:6b8383dc-d76a-493b-a91b-12f155ca0a51", "url": "https://sharemaestro.com/market-watch/natera-ntra-weekly-surge-322-close/", "external_url": null, "title": "Natera Inc (NTRA) closes at $322.10 after 20.3% weekly surge", "content_text": "The diagnostics stock\u2019s latest weekly move extended a sharp three-month advance, with turnover running above its recent average.", "date_published": "2026-08-14T15:14:53.917779+00:00", "authors": [{"name": "Sharemaestro Market Watch"}], "tags": ["Weekly signal", "NTRA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NTRA", "name": "Natera Inc", "sentiment_url": "https://sharemaestro.com/sentiment/125f8cfb-18df-4bd2-a1a4-c526de810e9b/"}]}}, {"id": "source:2bbfb8e944a917d519505f6e563f6028bb7ec27ee39686f959bc726292ae6904", "url": "https://finance.yahoo.com/healthcare/articles/hims-hers-hims-raised-guidance-151415471.html", "external_url": "https://finance.yahoo.com/healthcare/articles/hims-hers-hims-raised-guidance-151415471.html", "title": "Hims & Hers (HIMS) Raised Guidance. Can Growth Survive Its GLP-1 Margin Reset?", "content_text": "Hims & Hers Health, Inc. (NYSE:HIMS) shares fell over 6% in extended trading on August 10 after the telehealth company delivered another quarter of rapid growth alongside sharply weaker profitability. Revenue rose 38% year over year to $753.2 million, subscribers increased 19% to 2.89 million, and Monthly Revenue per Average Subscriber climbed 21% to $92. The company also raised its full-year revenue outlook to $3.1 billion to $3.3 billion from $2.8 billion to $3.0 billion. The earnings line told a different story. Hims reported an $86.3 million net loss, equal to 37 cents per share, compared ", "date_published": "2026-08-14T15:14:15+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Guidance", "HIMS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "Hims Hers Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/494d8676-2cc6-4860-bdb4-37e9e4702e1f/"}]}}, {"id": "source:52ad4603ac245cae116035e468d0e14a2e773fce3ed16737918ac6e720acbe0f", "url": "https://finance.yahoo.com/healthcare/articles/resmed-rmd-q4-2026-earnings-151328568.html", "external_url": "https://finance.yahoo.com/healthcare/articles/resmed-rmd-q4-2026-earnings-151328568.html", "title": "ResMed (RMD) Q4 2026 Earnings Call Transcript", "content_text": "Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Investor Relations Officer-Salli Schwartz Chairman and Chief Executive Officer-Mick Farrell Chief Financial Officer-Aaron Bloomer Full Conference Call Transcript Operator: Hello, and welcome to the Q4 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin, and I'll be your operator for today's call. At this time, all participants are in a listen-only mode. Please note this conference call is being recorded. Later, we'll conduct a question-and-answer session. Let me hand the call over ", "date_published": "2026-08-14T15:13:28+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "RMD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RMD", "name": "ResMed Inc", "sentiment_url": "https://sharemaestro.com/sentiment/c28a1de4-d485-455d-b927-eaa8ea7d6ba9/"}]}}, {"id": "source:389850c403f2757e33de95a32631226fc9da5cbfecf27e99c27ce42f766f9747", "url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOTTNjZnNqRkdfaThrcWxsUmZQb2g5N3p2ek5YQThfM0lGRHlFYUVZMHBzOHoxQkM5R2E3QkY1RHVlSXU4WmlMTFd3OWxRNzJVa1RmbGFyLV9oc3o2NmtLcEN6LWhkS20zWFBPeHBHUV9weDdhZU14cktEeU5DTE81SERjbkFIb09pSUpyX0h4SkxzMXlsM1BxYm8tdjZIUHZseEM1TzhBcC1xd29hWkxKWWdkSXlOZGk3c3RScWd4NjhCQnRvenhkQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiyAFBVV95cUxOTTNjZnNqRkdfaThrcWxsUmZQb2g5N3p2ek5YQThfM0lGRHlFYUVZMHBzOHoxQkM5R2E3QkY1RHVlSXU4WmlMTFd3OWxRNzJVa1RmbGFyLV9oc3o2NmtLcEN6LWhkS20zWFBPeHBHUV9weDdhZU14cktEeU5DTE81SERjbkFIb09pSUpyX0h4SkxzMXlsM1BxYm8tdjZIUHZseEM1TzhBcC1xd29hWkxKWWdkSXlOZGk3c3RScWd4NjhCQnRvenhkQQ?oc=5", "title": "Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore", "content_text": "Bristol Myers Squibb stock gains support from new multiple myeloma approval and raised earnings fore", "date_published": "2026-08-14T14:41:41+00:00", "authors": [{"name": "AD HOC NEWS"}], "tags": ["Earnings", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:97c858d35b442adeaa8782f828f3b3b4247965e763be76be63826112f55ef2e8", "url": "https://www.stocktitan.net/sec-filings/DGX/schedule-13g-a-quest-diagnostics-inc-amended-passive-investment-discl-c70a833ad4c8.html", "external_url": "https://www.stocktitan.net/sec-filings/DGX/schedule-13g-a-quest-diagnostics-inc-amended-passive-investment-discl-c70a833ad4c8.html", "title": "T. Rowe Price Associates (DGX) discloses 5.43M Quest Diagnostics shares in 13G/A", "content_text": "T. Rowe Price Associates, Inc. filed an amended Schedule 13G, reporting a beneficial ownership of 5,428,244 shares, or 4.9% of Quest Diagnostics Inc. common stock. The firm holds sole voting power over 5,321,387 shares and sole dispositive power over all 5,428,244 shares, while explicitly denying beneficial ownership. This filing provides key figures on their holdings and control over Quest Diagnostics shares.", "date_published": "2026-08-14T14:39:51+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "DGX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "DGX", "name": "Quest Diagnostics Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/e6a96f2d-1f29-46d8-a1e2-57c92ab8ff92/"}]}}, {"id": "source:3ca12183a4b8fdaae81a0dbd2f4e8862aa042d23b16f40222e9bf12880a75edd", "url": "https://seekingalpha.com/news/4633323-smith-nephew-gaap-eps-of-036-revenue-of-16b?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633323-smith-nephew-gaap-eps-of-036-revenue-of-16b?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Smith & Nephew GAAP EPS of $0.36, revenue of $1.6B", "content_text": "* Smith & Nephew press release [https://seekingalpha.com/filing/309951347] (SNN [https://seekingalpha.com/symbol/SNN]): Q2 GAAP EPS of $0.36. * Revenue of $1.6B (+3.2% Y/Y). * Trading profit for the first half reached $566M, an 8.10% increase year-over-year, expanding the trading profit margin by 60 bps to 18.30%. * Cash generated from operations reached $605M. MORE ON SMITH & NEPHEW * Smith & Nephew plc (SNN) Q2 2026 Earnings Call Transcript [https://seekingalpha.com/article/4929913-smith-and-nephew-plc-snn-q2-2026-earnings-call-transcript] * Smith & Nephew plc 2026 Q2 - Results - Earnings Ca", "date_published": "2026-08-14T14:35:40+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "SNN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNN", "name": "Smith & Nephew SNATS Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ca69f5b7-163b-4513-bb18-82a6766befe6/"}]}}, {"id": "source:f416de22cf631a3dbb7c98bcacc462420785fb07888215087741b995fd8451b6", "url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPUlJxM1AtejljN2h0cGs2UU00SEdzcnJ3VERvNFdhOUEzUHpaNHczSzgzOC1RY0QtS0dDUHhaODNwZXhnTVF1VmZHOXBKVmxZRFNHUmFFY294Vm92R29VMHJ3S2xhcGhfQUIxaXVKUHg2U1FGakExcDJ0dWtEc3VLMDhWalJsMVl0MThnOXpTVF9VbU1qcEQ3SHppN210WkpzTFZrOUxCWmNkWGx5SFhZQmFQNy1PQQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMitgFBVV95cUxPUlJxM1AtejljN2h0cGs2UU00SEdzcnJ3VERvNFdhOUEzUHpaNHczSzgzOC1RY0QtS0dDUHhaODNwZXhnTVF1VmZHOXBKVmxZRFNHUmFFY294Vm92R29VMHJ3S2xhcGhfQUIxaXVKUHg2U1FGakExcDJ0dWtEc3VLMDhWalJsMVl0MThnOXpTVF9VbU1qcEQ3SHppN210WkpzTFZrOUxCWmNkWGx5SFhZQmFQNy1PQQ?oc=5", "title": "Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings", "content_text": "Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings", "date_published": "2026-08-14T14:33:44+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "CELC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CELC", "name": "Celcuity LLC", "sentiment_url": "https://sharemaestro.com/sentiment/c797b78b-4fee-4542-836b-4cb097d61c43/"}]}}, {"id": "source:852b3b07ad31df79f03ca445f9208d142914d3a00060c060f1b819149361791a", "url": "https://www.globenewswire.com/news-release/2026/08/14/3345452/0/en/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-august-31-2026-in-insulet-corporation-lawsuit-podd.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/14/3345452/0/en/the-gross-law-firm-reminds-shareholders-of-a-lead-plaintiff-deadline-of-august-31-2026-in-insulet-corporation-lawsuit-podd.html", "title": "The Gross Law Firm Reminds Shareholders of a Lead Plaintiff", "content_text": "The Gross Law Firm is alerting shareholders of Insulet Corporation (NASDAQ: PODD) about a lead plaintiff deadline of August 31, 2026, in a class action lawsuit. The lawsuit alleges that Insulet made materially false and/or misleading statements regarding defective manufacturing controls that created a risk of product safety violations. Shareholders who purchased PODD shares between February 21, 2025, and May 26, 2026, are encouraged to contact the firm regarding potential lead plaintiff appointment.", "date_published": "2026-08-14T14:30:18+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Regulatory and legal", "PODD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/c1a60e73-081a-460a-9198-1d9e143774bc/"}]}}, {"id": "source:248efd7b0396e455702198e5194d740438aa7b88a4d03f1dc91e1f93d1f33f1b", "url": "https://www.investing.com/news/sec-filings/labcorp-announces-executive-leadership-changes-effective-in-september-93CH-4860896", "external_url": "https://www.investing.com/news/sec-filings/labcorp-announces-executive-leadership-changes-effective-in-september-93CH-4860896", "title": "Labcorp announces executive leadership changes effective in September", "content_text": "Labcorp (NYSE:LH) has announced executive leadership changes effective in September. Megan D. Bailey is resigning as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026. Brian J. Caveney, M.D., will assume an expanded role as Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, responsible for both Early Development Research Laboratories and Central Laboratories businesses, effective September 1, 2026. The company also recently reported strong second-quarter results, surpassing Wall Street expectations, with adjusted earnings of $4.99 per share and revenue of $3.73 billion, and has raised its full-year outlook.", "date_published": "2026-08-14T14:04:33+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Earnings", "LH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LH", "name": "Laboratory Corporation of America Holdings", "sentiment_url": "https://sharemaestro.com/sentiment/85aa6122-bac1-42e4-9d40-29c4d3d605d0/"}]}}, {"id": "source:454e441e5c05a4eed962c9b68d89915dae9e02ce2fa00c915f7ae52f7adf8cab", "url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBYTmxoSnhPdkFXNHRSXzVkX1E4aUFXcnZIMHZ3NWswOVZadjFFMDZJRGRTMXppNm8tTmw0NFRWLWNqTElJT2dmV0N3Q0Y0T29xRDN2bEkxOXdnNzNZaFk4M3gzOUpaZTlNX3pQYVZlTWkySUxPamptV3I4QkZ4YUU?oc=5", "external_url": "https://news.google.com/rss/articles/CBMif0FVX3lxTFBYTmxoSnhPdkFXNHRSXzVkX1E4aUFXcnZIMHZ3NWswOVZadjFFMDZJRGRTMXppNm8tTmw0NFRWLWNqTElJT2dmV0N3Q0Y0T29xRDN2bEkxOXdnNzNZaFk4M3gzOUpaZTlNX3pQYVZlTWkySUxPamptV3I4QkZ4YUU?oc=5", "title": "Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop", "content_text": "Hims & Hers Health raises 2023 revenue outlook after strong Q2 growth despite margin drop", "date_published": "2026-08-14T13:47:41+00:00", "authors": [{"name": "Pluang"}], "tags": ["Earnings", "HIMS"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "HIMS", "name": "Hims Hers Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/494d8676-2cc6-4860-bdb4-37e9e4702e1f/"}]}}, {"id": "source:386cb3630dec68a589d37ae6b2913b5157d6a00dddba542a858ad358a856d9fb", "url": "https://finance.yahoo.com/healthcare/articles/why-did-oscar-health-oscr-133340254.html", "external_url": "https://finance.yahoo.com/healthcare/articles/why-did-oscar-health-oscr-133340254.html", "title": "Why Did Oscar Health (OSCR) Fall After Record Profit and a Guidance Hike?", "content_text": "Oscar Health, Inc. (NYSE:OSCR) shares closed 11.9% lower at $26.54 on August 6, even after the insurer reported its most profitable first half and raised its full-year outlook. Second-quarter revenue rose 70% year over year to $4.88 billion, while the company swung to net income of $361.8 million from a $228.4 million loss. The stock recovered 5.1% the following day but still ended 7.3% below its pre-earnings close. The reversal was especially striking because OSCR had climbed roughly 110% in 2026 before the report. Investors had already rewarded the company for appearing to emerge from the Af", "date_published": "2026-08-14T13:33:40+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "OSCR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "OSCR", "name": "Oscar Health Inc", "sentiment_url": "https://sharemaestro.com/sentiment/4fa9b7e2-73ac-4384-b984-a811dc343c5c/"}]}}, {"id": "source:2c4fb12ff97bedcb851b595a51e3e121d4052a8c39e62b3eda842c7bbf3b2aac", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPVFVRTGtJLXVndnpRWGgwUG5vVXZfRE9lMnhmM1ItR0RFclBFcWx0STN3NWFORF84QjluMFZES0tUMzVjOG00aEtjZlUybVNXbFhtaTR2U3dqeXRLRDM4QmhYMDF3amVmM1FkajNSRUpKMGtFclhrc2VXQ1J3LTFsRy1icU1ka25NQlhHcU11Q1hPb0w0YkVtYS1ReHRpV21IOTQtLWJuTDVtWUVjQzhsYzI1dXN3Z0g5V2lIUS1mV3I1eVpQM19tNmVLVm1qWm5pOFB6a0xudw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPVFVRTGtJLXVndnpRWGgwUG5vVXZfRE9lMnhmM1ItR0RFclBFcWx0STN3NWFORF84QjluMFZES0tUMzVjOG00aEtjZlUybVNXbFhtaTR2U3dqeXRLRDM4QmhYMDF3amVmM1FkajNSRUpKMGtFclhrc2VXQ1J3LTFsRy1icU1ka25NQlhHcU11Q1hPb0w0YkVtYS1ReHRpV21IOTQtLWJuTDVtWUVjQzhsYzI1dXN3Z0g5V2lIUS1mV3I1eVpQM19tNmVLVm1qWm5pOFB6a0xudw?oc=5", "title": "AMN Healthcare Services (NYSE:AMN) Stock Price Expected to Rise, Citizens Jmp Analyst Says", "content_text": "AMN Healthcare Services (NYSE:AMN) Stock Price Expected to Rise, Citizens Jmp Analyst Says", "date_published": "2026-08-14T13:13:53+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "AMN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMN", "name": "AMN Healthcare Services Inc", "sentiment_url": "https://sharemaestro.com/sentiment/42b6a61f-5fd4-42a5-8c96-f4bbe14ea8fc/"}]}}, {"id": "source:701a5ab6e8f3aa07836a63bfd5bb6625190117c83e6221455cca8d9c0e5fecc1", "url": "https://www.globenewswire.com/news-release/2026/08/14/3345368/0/en/attention-long-term-shareholders-of-ars-pharmaceuticals-inc-nasdaq-spry-bloom-energy-corporation-nyse-be-erasca-inc-nasdaq-eras-and-insulet-corporation-nasdaq-podd-grabar-law-offic.html", "external_url": "https://www.globenewswire.com/news-release/2026/08/14/3345368/0/en/attention-long-term-shareholders-of-ars-pharmaceuticals-inc-nasdaq-spry-bloom-energy-corporation-nyse-be-erasca-inc-nasdaq-eras-and-insulet-corporation-nasdaq-podd-grabar-law-offic.html", "title": "Attention Long-Term Shareholders of ARS Pharmaceuticals, Inc. (NASDAQ: SPRY); Bloom Energy Corporation (NYSE: BE); Erasca, Inc. (NASDAQ: ERAS); and Insulet Corporation (NASDAQ: PODD): Grabar Law Office is Investigating Claims on Your Behalf", "content_text": "Grabar Law Office is investigating potential breaches of fiduciary duty by officers and directors of ARS Pharmaceuticals, Inc., Bloom Energy Corporation, Erasca, Inc., and Insulet Corporation. The investigations concern various allegations including misleading statements regarding product timelines, supply chain reliance, and manufacturing issues, which led to significant stock declines for these companies. Long-term shareholders are encouraged to contact the law office to explore options for corporate reforms and recovery of funds.", "date_published": "2026-08-14T13:03:57+00:00", "authors": [{"name": "GlobeNewswire"}], "tags": ["Market update", "PODD"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "PODD", "name": "Insulet Corporation", "sentiment_url": "https://sharemaestro.com/sentiment/c1a60e73-081a-460a-9198-1d9e143774bc/"}]}}, {"id": "source:8ecc71e5b3427760d6e2b90b96fce54588bfd8b7468363511d6c6dbca4d0c59a", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZkp6aTdaWUhLUExHQUxKVjRqS1hEZmJKVTJaYzhCM1ppNndtRS1qaG5RcGtraThjdEdRM3k5WWhyOWlzcmJocTVrZk94VzQ0bEJsN3U0dTFhUldUeHFDQ1ZTc191OE9FdUc3RDlQd0Y4YzZ2M2lCRFM2cVQzaGpybkJiV3dfcnd0a0M2ejFGQjdIOUltQU55M2VEZmo3b1FQTUJxd2J2SzJfanVYN201dzFDZw?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxOZkp6aTdaWUhLUExHQUxKVjRqS1hEZmJKVTJaYzhCM1ppNndtRS1qaG5RcGtraThjdEdRM3k5WWhyOWlzcmJocTVrZk94VzQ0bEJsN3U0dTFhUldUeHFDQ1ZTc191OE9FdUc3RDlQd0Y4YzZ2M2lCRFM2cVQzaGpybkJiV3dfcnd0a0M2ejFGQjdIOUltQU55M2VEZmo3b1FQTUJxd2J2SzJfanVYN201dzFDZw?oc=5", "title": "Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame", "content_text": "Capricor Therapeutics (CAPR) Stock Surges on FDA Application Ame", "date_published": "2026-08-14T12:54:24+00:00", "authors": [{"name": "GuruFocus"}], "tags": ["Market update", "CAPR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CAPR", "name": "Capricor Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/e2b47bef-4e47-4d5a-b1b8-a7d99654827c/"}]}}, {"id": "source:7ba1d3628a22e20904f590ae55776bd8abc7a9e5c7beffe9727b8a9ba60ce42c", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales", "content_text": "Natera (NTRA) Stock Looks Reasonable On Cash Flow But Rich On Sales", "date_published": "2026-08-14T12:46:29+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Balance sheet", "NTRA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NTRA", "name": "Natera Inc", "sentiment_url": "https://sharemaestro.com/sentiment/125f8cfb-18df-4bd2-a1a4-c526de810e9b/"}]}}, {"id": "source:830070169b6bb69b064a4ed30cb244706b616273074d7de5e549e69dae8f2248", "url": "https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-94722b0d78ba.html", "external_url": "https://www.stocktitan.net/sec-filings/TWST/schedule-13g-a-twist-bioscience-corp-amended-passive-investment-discl-94722b0d78ba.html", "title": "Twist Bioscience (TWST): EdgePoint discloses 4.21% beneficial stake in amended 13G", "content_text": "EdgePoint Investment Group Inc. has filed an amended Schedule 13G, disclosing a 4.21% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,521,635 shares as of June 30, 2026. The filing indicates EdgePoint acts as an investment manager for various funds that directly own these shares, with holdings representing 5% or less of the class. EdgePoint holds sole voting and dispositive power over 1,945,483 shares, and shared power over 576,152 shares.", "date_published": "2026-08-14T12:43:35+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "TWST"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "TWST", "name": "Twist Bioscience Corp", "sentiment_url": "https://sharemaestro.com/sentiment/869ebde0-6a03-4e36-bf0e-afe9f9df4ec0/"}]}}, {"id": "source:716db2c758fe7563d890b3fd84cd08700f39c2dc0800cb2ca92c80723134e873", "url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633188-lantheus-tau-pet-imaging-agent-approved-alzheimers?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Lantheus gains FDA nod for tau PET imaging agent in Alzheimer\u2019s", "content_text": "[US Food and Drug Administration (FDA)] Lantheus Holdings (LNTH [https://seekingalpha.com/symbol/LNTH]) on Friday announced the FDA approval of Tauklarify, a radiodiagnostic agent designed to identify tau pathology of the brain in adults with Alzheimer\u2019s disease through positron emission tomography (PET). Specifically, the approval allows the use of Tauklarify in cognitively impaired adults who are investigated for Alzheimer\u2019s disease to detect if there is any tau neurofibrillary tangle pathology causing the condition. Patients should undergo diagnostic tests, such as PET scans, to determine t", "date_published": "2026-08-14T12:31:50+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Regulatory and legal", "LNTH"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LNTH", "name": "Lantheus Holdings Inc", "sentiment_url": "https://sharemaestro.com/sentiment/41a59536-c8b5-4d85-a0e6-acfdd4b6ccea/"}]}}, {"id": "source:aece32cbceb89690dda7a95a948f5c558c8baa9211a9ec2cdde2a081b4c11af6", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOYWVtU1ltZ2FyZWM2WEQ4dWxjYW1kQWsxZjhKVDJubFY3NDFvS3ZuZURyUEhwR0F4SWRvUWxPdjE5WVN0YVNpOU90em5oR25FX19EbkRLeG9jZ05qd09aYkw2NFFwa2E5UnZTZnFmMVROY2ExSk5WUWZyUnVGZURLVlR0aDVYR3pKX2R2TW9NWk9qWGwwTHVHQ3BEcFJIemdVNzNXcy1uYkR4U0ZoXy0zcGN1UlliTFZYOEJFbG1nWDlWWWpu?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxOYWVtU1ltZ2FyZWM2WEQ4dWxjYW1kQWsxZjhKVDJubFY3NDFvS3ZuZURyUEhwR0F4SWRvUWxPdjE5WVN0YVNpOU90em5oR25FX19EbkRLeG9jZ05qd09aYkw2NFFwa2E5UnZTZnFmMVROY2ExSk5WUWZyUnVGZURLVlR0aDVYR3pKX2R2TW9NWk9qWGwwTHVHQ3BEcFJIemdVNzNXcy1uYkR4U0ZoXy0zcGN1UlliTFZYOEJFbG1nWDlWWWpu?oc=5", "title": "Mizuho raises Belite Bio stock price target to $220 on NDA progress", "content_text": "Mizuho raises Belite Bio stock price target to $220 on NDA progress", "date_published": "2026-08-14T12:16:19+00:00", "authors": [{"name": "Investing.com"}], "tags": ["Analyst action", "BLTE"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BLTE", "name": "Belite Bio Inc ADR", "sentiment_url": "https://sharemaestro.com/sentiment/623924bc-d175-483e-98a6-d82304cdb374/"}]}}, {"id": "source:6f3ad19d45a6717c24f32fbbfc13925fbc5ddd56cad0c94e00daaf0deab9b172", "url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/amgen-amgn-stock-looks-undervalued-120946360.html", "title": "Amgen (AMGN) Stock Looks Undervalued With A 37% Fair Value Gap", "content_text": "Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE. Amgen stock has delivered strong gains over the past five years, yet the current share price sits at a discount to an intrinsic value estimate based on a Discounted Cash Flow (DCF) model, while broader valuation checks point to a more mixed picture. Amgen has returned 116.3% over the past five years, which puts more weight on whether the current valuation still leaves room for an attractive long term outcome. Plans to open a", "date_published": "2026-08-14T12:09:46+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "AMGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc", "sentiment_url": "https://sharemaestro.com/sentiment/350e2440-2381-4144-857c-f6e37633f654/"}]}}, {"id": "source:93a4cf39d41a8117416ec597abba7e1d003a024cc99d4cf3bad9664ed228a918", "url": "https://finance.yahoo.com/healthcare/articles/cencora-cor-leveraging-healthcare-growth-120601766.html", "external_url": "https://finance.yahoo.com/healthcare/articles/cencora-cor-leveraging-healthcare-growth-120601766.html", "title": "Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity", "content_text": "Alpha Wealth Funds, LLC, an investment management company, released its Q2 2026 letter for the \"Insiders Fund\". A copy of the letter is available to download here. The Fund lost 1.45% in June, while it was up 8.43% for the 2nd quarter and 0.75% YTD. This compares to the S&P 500's -0.95%, 15.2%, and 9.98% returns, respectively, over the same period. The fund underperformed while the S&P 500 and Nasdaq-100 posted their best quarter in six years. A significant factor in this decline is a ~30% concentration in Alphabet stock, which shifted from a cash-generating asset to a capital-intensive postur", "date_published": "2026-08-14T12:06:01+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "COR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "COR", "name": "Cencora Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/11ece199-d4bb-4648-a8f7-8eef3fd9e478/"}]}}, {"id": "source:01198b51c04c276d2cf844c8e445d30e012b41ef88aa54687d4596f739308e92", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTGxLc2g1T1pKOU4ySDlsazNZY2ZoeDFyZWtjTmFreHlYeXVCa3h0bUJVYzVmS1VUZ1pfT2FyR2JoZXc5Y0JWMlg3Tk1rUDJ6b3M0emlFSnJEVFBkTmdLVzNjclVia05Sc2hKTHJMNkpOaEFKWVhmVnVfVXpRby1VRy0wSW9WTDNWYjBQdkIyWmtQU2hYUzFwYUNVZ0JkT3E1VXVGV3Jva0g2V1k?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxOTGxLc2g1T1pKOU4ySDlsazNZY2ZoeDFyZWtjTmFreHlYeXVCa3h0bUJVYzVmS1VUZ1pfT2FyR2JoZXc5Y0JWMlg3Tk1rUDJ6b3M0emlFSnJEVFBkTmdLVzNjclVia05Sc2hKTHJMNkpOaEFKWVhmVnVfVXpRby1VRy0wSW9WTDNWYjBQdkIyWmtQU2hYUzFwYUNVZ0JkT3E1VXVGV3Jva0g2V1k?oc=5", "title": "Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update", "content_text": "Evaxion (NASDAQ: EVAX) sets August 20 call for Q2 2026 results and update", "date_published": "2026-08-14T12:05:57+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "EVAX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVAX", "name": "Evaxion Biotech AS", "sentiment_url": "https://sharemaestro.com/sentiment/a6ab708f-0025-43c2-a164-bafa4475e8c2/"}]}}, {"id": "source:c8ede8fbac31b85508c11dd7482371dd87781f0aac1c69d6cc28449346b93547", "url": "https://www.stocktitan.net/sec-filings/KLRA/schedule-13g-kailera-therapeutics-inc-passive-investment-disclosure-5-6168bcbf82fb.html", "external_url": "https://www.stocktitan.net/sec-filings/KLRA/schedule-13g-kailera-therapeutics-inc-passive-investment-disclosure-5-6168bcbf82fb.html", "title": "RTW Investments discloses 8.3% Kailera Therapeutics (KLRA) stake on Schedule 13G", "content_text": "RTW Investments, LP and Roderick Wong, M.D. have reported an 8.3% beneficial ownership stake in Kailera Therapeutics, Inc. (KLRA) through a Schedule 13G filing. This amounts to 10,776,820 shares of common stock, based on 129,565,608 shares outstanding as of May 20, 2026. Both reporting persons share voting and dispositive power over these shares, which are held by RTW Funds, with RTW Investments acting as their investment adviser.", "date_published": "2026-08-14T12:04:27+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Deals and strategy", "KLRA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KLRA", "name": "Kailera Therapeutics, Inc. Common Stock", "sentiment_url": "https://sharemaestro.com/sentiment/5aad7a09-fe4a-41af-9f48-13cdece5f3e5/"}]}}, {"id": "source:feb4c10773207b089470a45f64ed6c862c294f24a43dcb044c603c039d23c4d0", "url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "external_url": "https://finance.yahoo.com/m/c7509af1-9542-320b-b10c-f73523ccdd58/eli-lilly-stock-nears-buy.html", "title": "Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains", "content_text": "While Eli Lilly isn't a perfect technical setup, it's still a fundamental powerhouse that could be worth considering. Continue Reading", "date_published": "2026-08-14T12:00:27+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "LLY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LLY", "name": "Eli Lilly and Company", "sentiment_url": "https://sharemaestro.com/sentiment/a3de1341-9ac3-48e9-b8c9-18c93f3d6516/"}]}}, {"id": "source:8a4df3220b054156b94e1e78f3c681a8bcc34d8ad16b30e5caaef673f472a4ed", "url": "https://finance.yahoo.com/healthcare/articles/evaxion-announce-business-second-quarter-120000704.html", "external_url": "https://finance.yahoo.com/healthcare/articles/evaxion-announce-business-second-quarter-120000704.html", "title": "Evaxion to announce business update and second quarter 2026 financial results on August 20, 2026", "content_text": "Evaxion COPENHAGEN, Denmark, August 14, 2026 - Evaxion A/S (NASDAQ: EVAX) (\"Evaxion\"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology\u2122 platform, will provide a business update and report its second quarter 2026 financial results on Thursday August 20, 2026, before opening of the Nasdaq CM. Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. To join the conference call, listen to the presentation and ask verbal questions, please reg", "date_published": "2026-08-14T12:00:00+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "EVAX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "EVAX", "name": "Evaxion Biotech AS", "sentiment_url": "https://sharemaestro.com/sentiment/a6ab708f-0025-43c2-a164-bafa4475e8c2/"}]}}, {"id": "source:5965bab414293756232d024d36146d3247dbbdcadb0cb3071528fa9a52f92949", "url": "https://www.biospace.com/fda/bms-welcomes-new-multiple-myeloma-drug-as-generics-batter-current-portfolio", "external_url": "https://www.biospace.com/fda/bms-welcomes-new-multiple-myeloma-drug-as-generics-batter-current-portfolio", "title": "BMS welcomes new multiple myeloma drug as generics batter current portfolio", "content_text": "Bristol Myers Squibb (BMS) received accelerated FDA approval for Zenbexus (iberdomide) for multiple myeloma, offering a new revenue stream as generics severely impact sales of its existing drugs, Revlimid and Pomalyst. Zenbexus is projected to achieve over $1 billion in annual earnings by 2031, providing a crucial boost while BMS continues to manage the erosion of its older portfolio. This approval highlights BMS's CELMoD platform's potential, with another candidate currently under FDA review.", "date_published": "2026-08-14T11:41:23+00:00", "authors": [{"name": "BioSpace"}], "tags": ["Deals and strategy", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:4ceaa3b51fc3d9f9a56de7b9b52808a8f0bf3901e53299b4beb572429384ff3e", "url": "https://www.marketbeat.com/instant-alerts/west-pharmaceutical-services-nysewst-rating-lowered-to-hold-at-zacks-research-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/west-pharmaceutical-services-nysewst-rating-lowered-to-hold-at-zacks-research-2026-08-14", "title": "West Pharmaceutical Services (NYSE:WST) Rating Lowered to Hold at Zacks Research", "content_text": "Zacks Research downgraded West Pharmaceutical Services (NYSE:WST) from \"strong buy\" to \"hold\" despite the company reporting strong quarterly results, exceeding EPS and revenue estimates. The broader analyst consensus remains a \"Moderate Buy\" with an average price target of $368.08. West Pharmaceutical Services posted Q2 EPS of $2.37 on revenue of $872.3 million, a 13.8% increase year-over-year, and forecast full-year 2026 EPS between $8.85 and $9.05.", "date_published": "2026-08-14T11:40:20+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "STE"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "STE", "name": "STERIS plc", "sentiment_url": "https://sharemaestro.com/sentiment/7b7c4ffa-5b66-43bb-800e-531f7cb23e72/"}]}}, {"id": "source:5e8cb8d1db55de58109c566531b18d38719602ac17d59b9a8d046041f96b7326", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQSnRHWDg2dXJDLTRLUU1DWE9sTXBrMVNVQUNtWFlvMWJnUWlMR29hdDlZVVVhajdnTlA5UXpBS1hWU3hmaWRUNkVGcGFNQkdqMllDXy01cENiMWl1QUlRREZ6WUhvRWdRS3RsbUZPV2FQSFRtWUJ3ZFVlVENPdG1LS2JtNFN5WU1GNUY3MzVYMHlJWEd5ZXFpMHNrSUFremlNYWdKTG4wbnA1SUFIOHVaRFBGNlFTOEJwZ3dDTmtIOUJma0dybXd6YWZPOUQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxQSnRHWDg2dXJDLTRLUU1DWE9sTXBrMVNVQUNtWFlvMWJnUWlMR29hdDlZVVVhajdnTlA5UXpBS1hWU3hmaWRUNkVGcGFNQkdqMllDXy01cENiMWl1QUlRREZ6WUhvRWdRS3RsbUZPV2FQSFRtWUJ3ZFVlVENPdG1LS2JtNFN5WU1GNUY3MzVYMHlJWEd5ZXFpMHNrSUFremlNYWdKTG4wbnA1SUFIOHVaRFBGNlFTOEJwZ3dDTmtIOUJma0dybXd6YWZPOUQ?oc=5", "title": "Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14%", "content_text": "Kymera Therapeutics Stock 8-Day Winning Spree: Stock Climbs 14%", "date_published": "2026-08-14T11:25:19+00:00", "authors": [{"name": "Trefis"}], "tags": ["Market update", "KYMR"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "KYMR", "name": "Kymera Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/b900d6f5-bdf3-4a85-8519-c09cce792794/"}]}}, {"id": "source:c64b8e9316762e1768a52a06f503d2444de2b4638847742571fd283e0347bcb8", "url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOenRDWG9XTjRfOWVPbnkyamJ5LWlTVDQycVhzWU4tRTYxenZHdEZlaGllYkI4OUF5MmJQLUNlSEViQTdlMUhmSWpBdHpMTzVYVVQ5UzlrN1BtNFd3azVQVjNSRXotTDB6ejZ6bkExLTQ2eHVTd1lnSkxtemoyYmdrYV83Y1lJV201azhnNEJoSkVIUk01NF9OWWJSVks3TlNMVkJfZk90b3BFSFdBZWhXWnRsYVNYbF9GQ0lUcnlFVjZyR0tIVDV6X0hkWXgwbXZMeGJ0UGZ3?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1gFBVV95cUxOenRDWG9XTjRfOWVPbnkyamJ5LWlTVDQycVhzWU4tRTYxenZHdEZlaGllYkI4OUF5MmJQLUNlSEViQTdlMUhmSWpBdHpMTzVYVVQ5UzlrN1BtNFd3azVQVjNSRXotTDB6ejZ6bkExLTQ2eHVTd1lnSkxtemoyYmdrYV83Y1lJV201azhnNEJoSkVIUk01NF9OWWJSVks3TlNMVkJfZk90b3BFSFdBZWhXWnRsYVNYbF9GQ0lUcnlFVjZyR0tIVDV6X0hkWXgwbXZMeGJ0UGZ3?oc=5", "title": "Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA", "content_text": "Handelsbanken Fonder AB Purchases Shares of 160,900 Oruka Therapeutics, Inc. $ORKA", "date_published": "2026-08-14T11:15:14+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "ORKA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ORKA", "name": "Oruka Therapeutics, Inc.", "sentiment_url": "https://sharemaestro.com/sentiment/6d245a59-aaf2-49c2-b017-4ec0def04928/"}]}}, {"id": "source:a2d5c0aa3ce84c6bdb7ccd6744695004be27f5d9088f8f488a9afd7b1fcc2802", "url": "https://www.stocktitan.net/sec-filings/SNN/6-k-smith-nephew-plc-current-report-foreign-issuer-9e7e5c98b5b2.html", "external_url": "https://www.stocktitan.net/sec-filings/SNN/6-k-smith-nephew-plc-current-report-foreign-issuer-9e7e5c98b5b2.html", "title": "Smith+Nephew (SNN) lifts H1 2026 profit but cuts revenue growth outlook", "content_text": "Smith+Nephew reported a higher profit for the first half of 2026, with revenue reaching $3,097 million, an increase of 4.6% year-on-year, and trading profit up 8.1% to $566 million. Despite this profit growth, the company revised its full-year underlying revenue growth guidance downwards from \"around 6%\" to \"around 4%\" due to softer performance in Orthopaedics and Advanced Wound Bioactives. Management reiterated its targets for trading profit growth, free cash flow, and adjusted ROIC, banking on efficiency savings and a stronger second half driven by new product launches and market stabilization.", "date_published": "2026-08-14T11:12:53+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Earnings", "SNN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "SNN", "name": "Smith & Nephew SNATS Inc", "sentiment_url": "https://sharemaestro.com/sentiment/ca69f5b7-163b-4513-bb18-82a6766befe6/"}]}}, {"id": "source:4a3743dd6463ed105ffc9c1441902f440c6c025c3c9d0aedf7bd19fa086ad557", "url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "external_url": "https://finance.yahoo.com/healthcare/articles/amgen-amgn-opens-science-innovation-111231819.html", "title": "Amgen (AMGN) Opens New Science And Innovation Center In Hyderabad", "content_text": "Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. Amgen (NasdaqGS:AMGN) announced the opening of a new Science and Innovation Center in Genome Valley, Hyderabad, expanding its global research and development presence. The Hyderabad center is designed to integrate scientific capabilities with data and digital tools to support discovery and development of new medicines. This expansion adds another research hub to Amgen's global footprint and increases its geographic diversification in Asia. Amgen is not the only healthcare stock investing", "date_published": "2026-08-14T11:12:31+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Market update", "AMGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "AMGN", "name": "Amgen Inc", "sentiment_url": "https://sharemaestro.com/sentiment/350e2440-2381-4144-857c-f6e37633f654/"}]}}, {"id": "source:a3f5e54b1bc513caabef40cd59e043b01a52e34e062487654650d578a673dedb", "url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-stock-trades-111117444.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/ligand-pharmaceuticals-lgnd-stock-trades-111117444.html", "title": "Ligand Pharmaceuticals (LGND) Stock Trades Below Fair Value Following A 337% Run", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Ligand Pharmaceuticals stock has surged over the past five years, yet the valuation signals are split, with a Discounted Cash Flow (DCF) intrinsic value estimate pointing to meaningful upside while traditional market multiples suggest the shares are pricing in a richer outlook. Ligand Pharmaceuticals has delivered a very large 5 year return of 337.4%, which puts extra focus on whether the current price still offers a margin of safety. The recent expansion of its royalty portfolio ", "date_published": "2026-08-14T11:11:17+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "LGND"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "LGND", "name": "Ligand Pharmaceuticals Incorporated", "sentiment_url": "https://sharemaestro.com/sentiment/f1224815-cddd-4bfb-8dc3-fe2858461148/"}]}}, {"id": "source:f92f7f0c9693e24edb6712526166529b5a9529086404f842dfa5a969adb07aff", "url": "https://www.nasdaq.com/articles/ionis-stock-has-plunged-30-it-time-buy-beaten-down-stock", "external_url": "https://www.nasdaq.com/articles/ionis-stock-has-plunged-30-it-time-buy-beaten-down-stock", "title": "Ionis Stock Has Plunged 30%. Is It Time to Buy the Beaten-Down Stock?", "content_text": "Key Points Q2 revenue fell, but last year included a large one-time payment. There were other signs of trouble in the earnings report. Wall Street is still bullish on the shares.10 stocks we like better than Ionis Pharmaceuticals \u203a Shares of Ionis Pharmaceuticals(NASDAQ: IONS) fell from about $86 in July to roughly $56 today, and are down about 30% year to date. The drop can be traced back to its heart drug Eplontersen failing to prove its efficacy, but it's just one symptom in a vast array of potential issues outlined in its recent second-quarter report. Image source: Getty Images. Missed Nvi", "date_published": "2026-08-14T10:35:00+00:00", "authors": [{"name": "nasdaq.com"}], "tags": ["Earnings", "ARWR"], "_sharemaestro": {"country": "United States", "coverage": "Provider-linked mention", "market_context": null, "companies": [{"symbol": "ARWR", "name": "Arrowhead Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/3b024d07-a80f-48f0-bbda-6bb79c593c64/"}]}}, {"id": "source:e4d01bbbf146aa4ec355ea8fe083db55400ff7e4df5d584bb2680379e03bd775", "url": "https://news.google.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?oc=5", "external_url": "https://news.google.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?oc=5", "title": "How Cigna\u2019s Dividend Hike And Jefferies\u2019 Downgrade At Cigna Group (CI) Has Changed Its Investment Story", "content_text": "Cigna Group recently declared a US$1.56 per share cash dividend with an ex-dividend date of September 8, 2026, while Jefferies downgraded its rating to 'hold' due to anticipated 2027 earnings headwinds. This situation highlights a tension between management's commitment to returning capital to shareholders and concerns about future earnings pressures and regulatory scrutiny of PBM practices. The article suggests investors should consider multiple perspectives and Cigna's resilience amidst changing industry dynamics.", "date_published": "2026-08-14T10:33:38+00:00", "authors": [{"name": "simplywall.st"}], "tags": ["Capital return", "CI", "DVA"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CI", "name": "Cigna Corp", "sentiment_url": "https://sharemaestro.com/sentiment/32048ab7-a095-49ef-9079-0ff1160342c4/"}, {"symbol": "DVA", "name": "DaVita HealthCare Partners Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bc454156-cf6a-4330-8e23-013562fc8248/"}]}}, {"id": "source:611c3c7e6d9823abbad41de0d6d89812c8b0824bb262f604ee9ed7202f98c020", "url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "external_url": "https://finance.yahoo.com/healthcare/articles/boston-scientific-bsx-faces-growth-102442230.html", "title": "Boston Scientific (BSX) Faces Growth Slowdown in Key Businesses", "content_text": "Parnassus Investments, an investment management company, released the \"Parnassus Core Equity Fund\" second quarter of 2026 investor letter. A copy of the letter can be downloaded here. The fund returned 16.83% in the second quarter of 2026, outperforming the S&P 500's 15.20% gain. Performance was supported by holdings in Information Technology and Communication Services, as well as the fund's lack of Energy exposure, while Financials and Health Care detracted. The fund is positioning for long-term growth through AI infrastructure, semiconductors, electrification and industrial automation, while", "date_published": "2026-08-14T10:24:42+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Macro sensitivity", "BSX"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BSX", "name": "Boston Scientific Corp", "sentiment_url": "https://sharemaestro.com/sentiment/486ab989-f120-4769-ae89-ae0116149e46/"}]}}, {"id": "source:69e41aa7e75f9ccc512ce8857abc35f4bdc160d3f676e2ad563cd137b39f126e", "url": "https://www.marketbeat.com/instant-alerts/filing-thomasville-national-bank-buys-shares-of-26575-abbvie-inc-abbv-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-thomasville-national-bank-buys-shares-of-26575-abbvie-inc-abbv-2026-08-14", "title": "Thomasville National Bank Buys Shares of 26,575 AbbVie Inc. $ABBV", "content_text": "Thomasville National Bank acquired a new stake of 26,575 shares in AbbVie Inc., valued at approximately $6.687 million, during the second quarter. AbbVie continues to show strong institutional interest, positive analyst sentiment with a \"Moderate Buy\" consensus and an average price target of $275.50, and recently exceeded quarterly earnings and revenue estimates. The company also offers a quarterly dividend of $1.73 per share, representing a 2.8% yield.", "date_published": "2026-08-14T10:24:05+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "ABBV"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ABBV", "name": "AbbVie Inc", "sentiment_url": "https://sharemaestro.com/sentiment/9a54a5f7-3445-44e1-a263-af644888772e/"}]}}, {"id": "source:0186585343a46a7d7d34fbc051bc32f552d01c8bd10d0bf5b491585b410abce5", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVDk0czRzV0JoaTZfT1k4dXVsQ1R4Z1RpZEg3TUVoWmpWN3ZpVDZSdlpwRjV1a091SEVFYnpRWFBXcTJPSUYxUHo4R0NGRVJyMlJmbm9XOWFjNVc1d3JJSjNmVWtZTTFxbUhXRDhsRU94bzB1blN1SGRCc0FsSXJCVUhndGFxRV9JR1U5WXZOcDlvMGlpaGFXQzRoMkpZYWM0SUo3SXU0c2FFaG1Ea2Z1OXk2TjhHemFL?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxQVDk0czRzV0JoaTZfT1k4dXVsQ1R4Z1RpZEg3TUVoWmpWN3ZpVDZSdlpwRjV1a091SEVFYnpRWFBXcTJPSUYxUHo4R0NGRVJyMlJmbm9XOWFjNVc1d3JJSjNmVWtZTTFxbUhXRDhsRU94bzB1blN1SGRCc0FsSXJCVUhndGFxRV9JR1U5WXZOcDlvMGlpaGFXQzRoMkpZYWM0SUo3SXU0c2FFaG1Ea2Z1OXk2TjhHemFL?oc=5", "title": "Signaturefd LLC Buys 22,148 Shares of Novo Nordisk A/S $NVO", "content_text": "Signaturefd LLC Buys 22,148 Shares of Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:19:38+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:112c5c0806e0952f7c4ad658563007404406e8007b16bb9ad0bb0233353a85c7", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNbUxaVGpOTU5oZFZxeXc2OVRUNEhMdElKNmJ1V2YyNWY0RVVqNWk5LTRhVVpBekNjMVl0R01QZG5kNDdId1FvWW5xaEhCNUVSclhyTkhodXBGaVQzRmRkWjk3alZYQW82akFWQi1oMWdxSXVWT2hYWUFOb3l5OFlWN2NNWDBmNmc5VnlSYXk5WURLVE9aTm1hZjhGbkRKdk41d2FrTHY5cWVVY0RFVUVPbS1LZ2JjMU03RjNVMmZEU3FwRFdhd2tSOFpLUi1ZWHFoUGVHWkR2VWZaTjg?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNbUxaVGpOTU5oZFZxeXc2OVRUNEhMdElKNmJ1V2YyNWY0RVVqNWk5LTRhVVpBekNjMVl0R01QZG5kNDdId1FvWW5xaEhCNUVSclhyTkhodXBGaVQzRmRkWjk3alZYQW82akFWQi1oMWdxSXVWT2hYWUFOb3l5OFlWN2NNWDBmNmc5VnlSYXk5WURLVE9aTm1hZjhGbkRKdk41d2FrTHY5cWVVY0RFVUVPbS1LZ2JjMU03RjNVMmZEU3FwRFdhd2tSOFpLUi1ZWHFoUGVHWkR2VWZaTjg?oc=5", "title": "Saratoga Research & Investment Management Sells 200,320 Shares of Novo Nordisk A/S $NVO", "content_text": "Saratoga Research & Investment Management Sells 200,320 Shares of Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:19:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:d40ad7328e447738b00d9f8d2159060f6a7d5d95c9f0ce102423e5ef35886830", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNRUZTSTM4YnBCVHo5dEVPY3lzYVo1M29wbmZsd0NUYTRjMVBmeEpvQ3U3R1BfczdvdkdaSmVVMl9ES1lha1FWSGgzb2hOZDZTRDBfTldMMk5KV0xSNWRybDg1SXJQajZKWUl6LXpXRDBHaXBGWWdLMm9JTDhJcmpoXzlkaGowSExtU0NQNzdiUDh1bl9Sby1ueHdVVkNyUWgwUFBvcUpWTFUzYk1lenR2QzdVbUxGdk9tUEY5RXgyMWxGMlU0UzFHOEltSmg4eXQ3R25MMkRLSEI?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNRUZTSTM4YnBCVHo5dEVPY3lzYVo1M29wbmZsd0NUYTRjMVBmeEpvQ3U3R1BfczdvdkdaSmVVMl9ES1lha1FWSGgzb2hOZDZTRDBfTldMMk5KV0xSNWRybDg1SXJQajZKWUl6LXpXRDBHaXBGWWdLMm9JTDhJcmpoXzlkaGowSExtU0NQNzdiUDh1bl9Sby1ueHdVVkNyUWgwUFBvcUpWTFUzYk1lenR2QzdVbUxGdk9tUEY5RXgyMWxGMlU0UzFHOEltSmg4eXQ3R25MMkRLSEI?oc=5", "title": "Merit Financial Group LLC Has $53.25 Million Stock Position in Johnson & Johnson $JNJ", "content_text": "Merit Financial Group LLC Has $53.25 Million Stock Position in Johnson & Johnson $JNJ", "date_published": "2026-08-14T10:19:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:ade001452edbf036d90da41d876ca5bb63cb3732a97ce55767440431e3ebb200", "url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPbjVjRGU0TTVSQ2ZIcThzRFA1UVdkUHN4ZGRYNzZPVHZ6akJBM1FnUFdTWlo4MXdiYVp0S3d5OEtid1FnR2NIMm9oRE5kRjdSM0FMaFlBd1R5dV9vYi1JUURuVW92YTJjTmZYREY1R0ZDR09nT3A1Qy1wYml2dU1kVEsxVU9JcGc2V3ZkSnA3QkFPbVVTcG1fZV9rRk42SjUwLXZueThmWlFfSGNrTFdlOEkxSklnN1A5VXM1UTRmRjVCd0pvTkY2NzMweVRNSkNYN0lXRGhtSQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi1wFBVV95cUxPbjVjRGU0TTVSQ2ZIcThzRFA1UVdkUHN4ZGRYNzZPVHZ6akJBM1FnUFdTWlo4MXdiYVp0S3d5OEtid1FnR2NIMm9oRE5kRjdSM0FMaFlBd1R5dV9vYi1JUURuVW92YTJjTmZYREY1R0ZDR09nT3A1Qy1wYml2dU1kVEsxVU9JcGc2V3ZkSnA3QkFPbVVTcG1fZV9rRk42SjUwLXZueThmWlFfSGNrTFdlOEkxSklnN1A5VXM1UTRmRjVCd0pvTkY2NzMweVRNSkNYN0lXRGhtSQ?oc=5", "title": "Johnson & Johnson $JNJ Stock Holdings Decreased by Gateway Investment Advisers LLC", "content_text": "Johnson & Johnson $JNJ Stock Holdings Decreased by Gateway Investment Advisers LLC", "date_published": "2026-08-14T10:19:37+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:a5b894bbb17dde7522ff31e80d46acc8da16167c23fec3bd80b43db10bed098e", "url": "https://www.marketbeat.com/instant-alerts/filing-monument-capital-management-decreases-stake-in-gilead-sciences-inc-gild-2026-08-14", "external_url": "https://www.marketbeat.com/instant-alerts/filing-monument-capital-management-decreases-stake-in-gilead-sciences-inc-gild-2026-08-14", "title": "Monument Capital Management Decreases Stake in Gilead Sciences, Inc. $GILD", "content_text": "Monument Capital Management significantly reduced its stake in Gilead Sciences by 56.1% in the second quarter, selling over 15,000 shares. Despite this, institutional investors collectively own 83.67% of the company, and analysts maintain a \"Moderate Buy\" consensus with an average price target of $158.04. Gilead also reported strong quarterly earnings and declared a dividend of $0.82 per share.", "date_published": "2026-08-14T10:18:10+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Earnings", "GILD"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "GILD", "name": "Gilead Sciences Inc", "sentiment_url": "https://sharemaestro.com/sentiment/bed0290f-10c3-46eb-9ae3-e4a990955009/"}]}}, {"id": "source:db2aafec172f151dbbe74780c6349d009dd3eea1a998bbfc2c3f90bdb3f325cd", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPdDRmaUJDZVFQVFZpaFU1NHF2VG5zUHZKT0s1OTdHNE5HejRhc3VoQnF3NTVndG9jcl9oOHBLNFo1WmtCNW1KZUhWY21Cc0VKUm93UzZMb2hlRWt0QzVJYTFKejNsRlFEUFdTY29xUF9iWEZyVndFeWhUbUI2dXRaQ1FMeUdLUHBDQVBsUExkMTFzc0g1Y2pRZ3g4Z0xyVS1lTl9LTTVvWUhYWnVqYVpfLXRJalNIbE1oODItUF9QaF8wdm9lRkpFXzg2WnlBdXlmVWRV?oc=5", "external_url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxPdDRmaUJDZVFQVFZpaFU1NHF2VG5zUHZKT0s1OTdHNE5HejRhc3VoQnF3NTVndG9jcl9oOHBLNFo1WmtCNW1KZUhWY21Cc0VKUm93UzZMb2hlRWt0QzVJYTFKejNsRlFEUFdTY29xUF9iWEZyVndFeWhUbUI2dXRaQ1FMeUdLUHBDQVBsUExkMTFzc0g1Y2pRZ3g4Z0xyVS1lTl9LTTVvWUhYWnVqYVpfLXRJalNIbE1oODItUF9QaF8wdm9lRkpFXzg2WnlBdXlmVWRV?oc=5", "title": "Mirae Asset Global Investments Co. Ltd. Increases Stake in Novo Nordisk A/S $NVO", "content_text": "Mirae Asset Global Investments Co. Ltd. Increases Stake in Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:17:44+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Deals and strategy", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:3a46ef33160b83e5f52ede04dc5697cd45ead01cf871b99e78447d3d14fec3a6", "url": "https://www.marketscreener.com/news/bernstein-adjusts-pt-on-regeneron-pharmaceuticals-to-756-from-753-maintains-market-perform-rating-ce7859dede89f527", "external_url": "https://www.marketscreener.com/news/bernstein-adjusts-pt-on-regeneron-pharmaceuticals-to-756-from-753-maintains-market-perform-rating-ce7859dede89f527", "title": "Bernstein Adjusts PT on Regeneron Pharmaceuticals to $756 From $753, Maintains Market Perform Rating", "content_text": "Bernstein has increased its price target for Regeneron Pharmaceuticals (REGN) to $756 from $753, while maintaining a \"Market Perform\" rating on the stock. This adjustment reflects a modest change in the analyst's valuation, indicating a continued neutral stance on the company's stock performance. The news is part of a series of recent analyst adjustments for Regeneron, with other firms also revising their price targets.", "date_published": "2026-08-14T10:16:14+00:00", "authors": [{"name": "marketscreener.com"}], "tags": ["Analyst action", "REGN"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "REGN", "name": "Regeneron Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/1c42d613-c405-45d7-9f43-f2050c317cb4/"}]}}, {"id": "source:b7359b11cf1c82e265c7ba9a78174524918e023614d3696e8731450342705533", "url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNDgwdXdkU01vaC1mOGtHSGY4a2txOW9vYXk3bFowSlVWRVhhRk9ZbVNFTWJhZVBLS2dVbXoyYmxONi1iWkZ5Uk5KblY3ZTFLRy16TVpsaXlXS2NGOG9Pb3VYMDBHQlZXU2V4NU54N1gwZjBSd1RHeFFFeUxqZVdLVFhUUmpqa0NiOTNrLTlaRU5Eb0F2ZkdURUJiSFF1bkdxVUNVLUw1V09sNnE2NzVjYVljaDVzVHZQYm9fOUtKOUN3M1B0bVp0ZUh1Q0U?oc=5", "external_url": "https://news.google.com/rss/articles/CBMizAFBVV95cUxNNDgwdXdkU01vaC1mOGtHSGY4a2txOW9vYXk3bFowSlVWRVhhRk9ZbVNFTWJhZVBLS2dVbXoyYmxONi1iWkZ5Uk5KblY3ZTFLRy16TVpsaXlXS2NGOG9Pb3VYMDBHQlZXU2V4NU54N1gwZjBSd1RHeFFFeUxqZVdLVFhUUmpqa0NiOTNrLTlaRU5Eb0F2ZkdURUJiSFF1bkdxVUNVLUw1V09sNnE2NzVjYVljaDVzVHZQYm9fOUtKOUN3M1B0bVp0ZUh1Q0U?oc=5", "title": "17,243 Shares in Johnson & Johnson $JNJ Bought by Thomasville National Bank", "content_text": "17,243 Shares in Johnson & Johnson $JNJ Bought by Thomasville National Bank", "date_published": "2026-08-14T10:12:43+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:a1c08db8606a81946dc96237a7ac91198a7e095d10966702d650985bf2911dba", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxORGc4NFNkeWk0SDZHVmFfZXp1QkRUaWhjdWpYUGRDb1lDOXE1LXY0VXBTdWY4ZF8wMVZUMlZOTzg3akcxWXV5YTg0bjFqSEk5c1RXTlRMVm1OMlRxQnlzMGhuZVNRNWpsbEduUHZ3T1FrWWgzRldDaWFQLWRsVlptTWFHWFBlZVMtV2s3YjRVdjNyLVRSZnVkSHU1ZjJIMjNmR29MOXpLRzdEZ01ZUnVVd0lwbWNpUFVSWEsxeENMYjRwSzJybWtR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxORGc4NFNkeWk0SDZHVmFfZXp1QkRUaWhjdWpYUGRDb1lDOXE1LXY0VXBTdWY4ZF8wMVZUMlZOTzg3akcxWXV5YTg0bjFqSEk5c1RXTlRMVm1OMlRxQnlzMGhuZVNRNWpsbEduUHZ3T1FrWWgzRldDaWFQLWRsVlptTWFHWFBlZVMtV2s3YjRVdjNyLVRSZnVkSHU1ZjJIMjNmR29MOXpLRzdEZ01ZUnVVd0lwbWNpUFVSWEsxeENMYjRwSzJybWtR?oc=5", "title": "Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A", "content_text": "Rallybio Corp (RLYB) sees Balyasny group report 0% ownership in 13G/A", "date_published": "2026-08-14T10:09:50+00:00", "authors": [{"name": "Stock Titan"}], "tags": ["Market update", "RLYB"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "RLYB", "name": "Rallybio Corp", "sentiment_url": "https://sharemaestro.com/sentiment/8ae7d703-1a45-4a80-8791-d5a3afec4d6d/"}]}}, {"id": "source:bc0aa0447507eaf7a69603997d50a911aa68fc7e6c66948128d59e4af20b5d30", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQLWhlc29YUkFub2RJLXA5dG5KQjczZWd1N0dvTzM1TVlyWGROdXRJSVB1SU0xaXNFOHhjcUdLdVJKOE1GRTlqNHEwWnFzRUFpbmxDek04c3JIZEhLTXJGblZvWFF2RVV0UDMyc2IyOG9HWmppWHU4T3lkSnhVek11QkdWMFpuM3dnMDg2WjdTWUZRZmkwdTNqY2JDcVdfcFNobHRZc1FIMmR4cXVsRGw1eHVyY2VoYnloWHJYMUlR?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQLWhlc29YUkFub2RJLXA5dG5KQjczZWd1N0dvTzM1TVlyWGROdXRJSVB1SU0xaXNFOHhjcUdLdVJKOE1GRTlqNHEwWnFzRUFpbmxDek04c3JIZEhLTXJGblZvWFF2RVV0UDMyc2IyOG9HWmppWHU4T3lkSnhVek11QkdWMFpuM3dnMDg2WjdTWUZRZmkwdTNqY2JDcVdfcFNobHRZc1FIMmR4cXVsRGw1eHVyY2VoYnloWHJYMUlR?oc=5", "title": "MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research", "content_text": "MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research", "date_published": "2026-08-14T10:03:47+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Analyst action", "INKT"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "INKT", "name": "Mink Therapeutics Inc", "sentiment_url": "https://sharemaestro.com/sentiment/cc80f937-724a-42d1-a52d-0ddff4bf3d31/"}]}}, {"id": "source:abc1eae958c35109bfbcbe2674d0546f19c5f5ba61860997f67e4438ccac40f4", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbWNnU1NZR1F5OVQ4MThMdWtSb3FSSUduNFZma0lEb2x1cHcyNHBqQ3hYZzk1cHh1THVQUFlCOGlIVlNBaTRyTGZZWUlDR21WTGQ0aFBpMHNFUDhEaHY4QjR6ZGhHSUpRVFJBbTRNUGVnaE1reDV3NHN2YXgwTUxmNzJXdzhFc216TzRiREdBRmdlZE82eHZhZ1M0WFlNNC0zQ2pjOTlQdjhwMngzaFI4eS1Oc05raExJRzUxdW1QWQ?oc=5", "external_url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxNbWNnU1NZR1F5OVQ4MThMdWtSb3FSSUduNFZma0lEb2x1cHcyNHBqQ3hYZzk1cHh1THVQUFlCOGlIVlNBaTRyTGZZWUlDR21WTGQ0aFBpMHNFUDhEaHY4QjR6ZGhHSUpRVFJBbTRNUGVnaE1reDV3NHN2YXgwTUxmNzJXdzhFc216TzRiREdBRmdlZE82eHZhZ1M0WFlNNC0zQ2pjOTlQdjhwMngzaFI4eS1Oc05raExJRzUxdW1QWQ?oc=5", "title": "QV Investors Inc. Acquires 81,870 Shares of Novo Nordisk A/S $NVO", "content_text": "QV Investors Inc. Acquires 81,870 Shares of Novo Nordisk A/S $NVO", "date_published": "2026-08-14T10:01:30+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "NVO"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "NVO", "name": "Novo Nordisk A/S", "sentiment_url": "https://sharemaestro.com/sentiment/dec9b31b-80d3-4b59-9f61-3b8d5687d920/"}]}}, {"id": "source:5cadd270050a862f51b65048349581ab91089de3aac765544f5bf170a07ff2ac", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNR1lHUi1HWnpHUFRjZU90ZEhZX2dHNXpPX1ZjQktvZ01qZWdyejh2ZTVBWEhwVDJucy12eEJkYlhkYnEwYWRub2xaOGVVV0U5SXJxa2JxQ0JpZFdxdHN1ZExkNkcza2QzVHFQMmZ0V1pTTVRsb0VicGRDcGxjNDlrd0Vldk1rYVpCQy1GMW84UmtPRU1tN2tCVUlyZnJ6cWZ2SFhXZUxpaVp2NkpFSjVWcFI0TEZQWnJYSlpldW5lZ3dZWWtQb2ppb1ln?oc=5", "external_url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxNR1lHUi1HWnpHUFRjZU90ZEhZX2dHNXpPX1ZjQktvZ01qZWdyejh2ZTVBWEhwVDJucy12eEJkYlhkYnEwYWRub2xaOGVVV0U5SXJxa2JxQ0JpZFdxdHN1ZExkNkcza2QzVHFQMmZ0V1pTTVRsb0VicGRDcGxjNDlrd0Vldk1rYVpCQy1GMW84UmtPRU1tN2tCVUlyZnJ6cWZ2SFhXZUxpaVp2NkpFSjVWcFI0TEZQWnJYSlpldW5lZ3dZWWtQb2ppb1ln?oc=5", "title": "Johnson & Johnson $JNJ Shares Bought by Interchange Capital Partners LLC", "content_text": "Johnson & Johnson $JNJ Shares Bought by Interchange Capital Partners LLC", "date_published": "2026-08-14T10:01:30+00:00", "authors": [{"name": "MarketBeat"}], "tags": ["Market update", "JNJ"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "JNJ", "name": "Johnson & Johnson", "sentiment_url": "https://sharemaestro.com/sentiment/faf43de1-aad0-4aa0-98eb-93c011d3d249/"}]}}, {"id": "source:93d2c495d7c8b26f9cf1a13dc2803c9c9373e38139a22f7fd2fc0e7c257d634f", "url": "https://pmlive.com/pharma_news/bristol-myers-squibb-announces-new-2-3bn-campus-in-the-us", "external_url": "https://pmlive.com/pharma_news/bristol-myers-squibb-announces-new-2-3bn-campus-in-the-us", "title": "Bristol Myers Squibb announces new $2.3bn campus in the US", "content_text": "Bristol Myers Squibb has announced a new $2.3 billion multi-modal manufacturing campus in Houston, Texas, creating nearly 500 skilled jobs. This investment is part of BMS's $40 billion commitment to the US, aiming to accelerate the delivery of next-generation medicines. The campus's modular design and multi-modal capabilities will allow for flexible manufacturing of various medicine types, supporting the company's current and future pipeline.", "date_published": "2026-08-14T09:50:19+00:00", "authors": [{"name": "PMLiVE"}], "tags": ["Market update", "BMY"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "BMY", "name": "Bristol-Myers Squibb Company", "sentiment_url": "https://sharemaestro.com/sentiment/d302e92e-0d9f-411a-8823-7efba73d07cd/"}]}}, {"id": "source:00080bf9420de03300de7c149c296f3f345081ac0dcee7187c6ee511e8f63e22", "url": "https://finance.yahoo.com/markets/stocks/articles/centene-cnc-stock-still-looks-091638310.html", "external_url": "https://finance.yahoo.com/markets/stocks/articles/centene-cnc-stock-still-looks-091638310.html", "title": "Centene (CNC) Stock Still Looks Like A Bargain As Shares Jumped 145%", "content_text": "Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Centene stock has surged over the past year, yet the current checks still suggest it leans on the cheap side, so investors are weighing how much of the recent optimism is already reflected in the price. Centene has returned 145.2% over the past year, which puts a spotlight on whether the recent share price strength is outpacing the underlying fundamentals. Raised expectations for future revenue and earnings, together with a plan to redeem part of its debt, can support the case for", "date_published": "2026-08-14T09:16:38+00:00", "authors": [{"name": "finance.yahoo.com"}], "tags": ["Earnings", "CNC"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "CNC", "name": "Centene Corp", "sentiment_url": "https://sharemaestro.com/sentiment/1ec58871-c065-489e-a86e-07a90550bef4/"}]}}, {"id": "source:c2732936f28167b570efd9641ca2304365fff2c1225226bd6743c845f7f36a42", "url": "https://seekingalpha.com/news/4633062-eton-pharmaceuticals-jumps-on-strong-q2-print-2026-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "external_url": "https://seekingalpha.com/news/4633062-eton-pharmaceuticals-jumps-on-strong-q2-print-2026-guidance?amp%3Butm_medium=referral&amp%3Bfeed_item_type=news", "title": "Eton Pharmaceuticals jumps on strong Q2 print, 2026 guidance", "content_text": "Shares in Eton Pharmaceuticals (ETON [https://seekingalpha.com/symbol/ETON]) rallied 25% in premarket trading on Friday, driven by a solid quarterly print and 2026 revenue forecast, which the company said would exceed $145M while targeting adjusted EBITDA margin above 35%. Chief executive officer Sean Brynjelsen said the company delivered \u201crecord revenue, significant margin expansion, and important progress across both our commercial portfolio and pipeline,\u201d while also completing \u201cseveral strategic transactions\u201d intended to support long-term growth. On longer-term profitability, Brynjelsen sai", "date_published": "2026-08-14T09:13:08+00:00", "authors": [{"name": "seekingalpha.com"}], "tags": ["Earnings", "ETON"], "_sharemaestro": {"country": "United States", "coverage": "Main company", "market_context": null, "companies": [{"symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "sentiment_url": "https://sharemaestro.com/sentiment/18951d8f-f4c6-449a-a382-55fa05c2c1b2/"}]}}]}